4 March 2019
GlobalData’s primary research identified patients with high-risk disease as the highest unmet need population in MM.
4 December 2018
There is a lot of uncertainty as to what the UK healthcare industry will look like post-Brexit, with almost half of respondents in a recent global survey of industry professionals...
28 September 2018
The current competitive market for Alzheimer’s disease focuses only on symptomatic treatments, providing an opening for urgent new disease-modifying drugs (DMDs), according to a report by GlobalData.
12 September 2018
Biologic drugs are some of the most expensive medicines to develop, and due to recent trends in drug development and a continuing increase in the price of new medicines, there...
9 August 2018
Global Amyotrophic Lateral Sclerosis market expected to experience explosive growth by 2027, says GlobalData
Pharmaceutical companies target novel MOAs in a market with few approved therapies Amyotrophic lateral sclerosis (ALS) is a motor neuron degenerative disease that affects both upper motor neurons (UMN) and...
8 August 2018
Increasing patient population and launching new drugs will drive Acute Ischemic Stroke market growth, says GlobalData
Current Ischemic stroke drugs focus on revascularization and secondary stroke prevention Acute ischemic stroke (AIS) results from a complete blockage of a cerebral artery, leading to death of brain cells...
2 August 2018
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory loss, cognitive impairment, and functional decline. The cause of AD is unknown, but it appears to be multifactorial, with...
27 July 2018
Regenerative medicine has potential to displace current treatments in cardiovascular and metabolic disorders space, says GlobalData
New approvals expected to drive CVMD market growth Regenerative medicine is under the spotlight for its potential to repair or replace damaged or diseased human cells or tissues to restore...
5 July 2018
The global market for cancer immunotherapies currently tops $33bn in value, with Celgene, Bristol-Myers Squibb and Roche amongst the key players. The market is anticipated to exceed $103.4bn in sales...
5 July 2018
Binge eating disorder (BED) is the most common eating disorder in the US, however, the number of patients who receive treatment remains low because of an inadequate diagnosis rate. BED...